Close
Crestor® (rosuvastatin calcium)



 

Clinical Trial Results

Often doctors will use the results of (glossary term)clinical trials to help them evaluate different medications. The information and tools below show the results of two clinical trials for CRESTOR® (rosuvastatin calcium).

The first compares CRESTOR versus Lipitor® (atorvastatin calcium), another cholesterol-lowering medication, in a trial known as (glossary term)ECLIPSE (comparison of the effectiveness and safety of rosuvastatin and atorvastatin in high-risk patients with high cholesterol across doses and time points).

The second demonstrates how (video)bad (LDL) cholesterol was lowered in a clinical trial known as (glossary term)STELLAR (comparison of the effectiveness and safety of rosuvastatin in patients with high cholesterol versus simvastatin, atorvastatin, and pravastatin across doses).

This information is not meant to show which cholesterol medication is right for you. Ask your doctor about clinical trial results involving CRESTOR and what the results mean. Then, together, you can decide what action to take.

ECLIPSE Trial

CRESTOR vs Lipitor

About the ECLIPSE Trial
ECLIPSE was a 24-week clinical trial involving 1,036 high-risk patients who had high cholesterol at the beginning of the trial. Patients were given one of the following statin medications: CRESTOR® (rosuvastatin calcium) or Lipitor® (atorvastatin calcium). The researchers then compared the percentage of patients achieving bad (LDL) cholesterol goal at different dosages and time points (6, 12, 18, 24 weeks) between the two medicines. At each time point and dose comparison, significantly more high-risk patients taking CRESTOR achieved the guideline recommended goal of <100 mg/dL for bad (LDL) cholesterol versus Lipitor. The most common adverse events were muscle aches and pains, chest pains, and inflammation of the nose and throat.

In high-risk patients, per Treatment Guidelines, bad (LDL) cholesterol goal is <100 mg/dL.

STELLAR Trial

About the STELLAR Trial
STELLAR was a 6-week clinical trial involving 2,240 patients who had high cholesterol at the beginning of the trial. Patients were given different dosages of one of the following statin medications: CRESTOR® (rosuvastatin calcium), Lipitor® (atorvastatin calcium), Zocor® (simvastatin), and Pravachol® (pravastatin sodium). The researchers then compared the changes in the patients' LDL-C between the different drugs and dosages. In the STELLAR trial, the occurrence of adverse events was similar between treatment groups. The most common adverse events were pain, sore throat, muscle ache, and headache.

More Facts to Consider About CRESTOR

When diet and exercise alone aren't enough to lower your cholesterol, it's important to discuss your treatment options with your doctor and choose a medication that's right for you.

In high-risk patients, per Treatment Guidelines, bad (LDL) cholesterol goal is <100 mg/dL.



Please see full Prescribing Information for CRESTOR
http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=crestor&country=us&popup=no

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.



Clinical trial
Clinical trials are research studies conducted to evaluate the safety and effectiveness of medications. In a typical clinical trial, groups of patients are asked to take a certain medication. This may be a specific dose of an existing medication, a dose of a new medication, or a placebo (sugar pill). Researchers then gather data over time and analyze the results.
ECLIPSE trial
ECLIPSE was a 24-week clinical trial involving 1,036 high-risk patients who had high cholesterol at the beginning of the trial. Patients were given one of the following statin medications: CRESTOR® (rosuvastatin calcium) or Lipitor® (atorvastatin calcium). The researchers then compared the percentage of patients achieving bad (LDL) cholesterol goal at different dosages and time points (6, 12, 18, 24 weeks) between the two medicines. At each time point and dose comparison, significantly more high-risk patients taking CRESTOR achieved the guideline recommended goal of <100 mg/dL for bad (LDL) cholesterol versus Lipitor. The most common adverse events were muscle aches and pains, chest pains, and inflammation of the nose and throat.
STELLAR trial
STELLAR was a 6-week clinical trial involving 2,240 patients who had high cholesterol at the beginning of the trial. Patients were given different dosages of one of the following statin medications: CRESTOR® (rosuvastatin calcium), Lipitor® (atorvastatin calcium), Zocor® (simvastatin), and Pravachol® (pravastatin sodium). The researchers then compared the changes in the patients' LDL-C between the different drugs and dosages. In the STELLAR trial, the occurrence of adverse events was similar between treatment groups. The most common adverse events were pain, sore throat, muscle ache, and headache.